Importance of the dysregulation of the kynurenine pathway on cognition in schizophrenia: a systematic review of clinical studies
Authors:
- 2 December 2022
- journal article
- review article
- Published by Springer Nature in European Archives of Psychiatry and Clinical Neuroscience
- Vol. 273 (6) , 1317-1328
Abstract
Schizophrenia is a chronic psychotic disease burdened by cognitive deficits which hamper daily functioning causing disability and costs for society. Biological determinants underlying cognitive impairment are only partially understood and there are no convincing pharmacological targets able to improve cognitive outcome. Mounting evidence has shown the involvement of the kynurenine pathway in the pathophysiology of schizophrenia, also concerning cognitive symptoms. Therefore, the action of specific metabolites of kynurenine could affects cognition in schizophrenia. To evaluate the impact of the metabolites of kynurenine pathway on cognitive functions in schizophrenia spectrum disorders, with a focus on the modulating role of gender, to identify predictors of cognitive functioning and hypothetical pharmacological targets able to resize disability by improving cognition, thus functioning and quality of life. A systematic review was performed in PubMed/MEDLINE and Embase according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses. All studies measuring the direct impact of kynurenine metabolites on cognitive performances in living individuals with schizophrenia spectrum disorders were included in the review. Six studies were included. The activation of the kynurenine pathway resulted associated with greater cognitive deficits in patients with schizophrenia and both elevations and reduction of metabolites seemed able to affect cognitive outcome. No modulating role of sex emerged. This systematic review provides evidence that the activation of the kynurenine pathway affects cognition in patients with schizophrenia and highlights this pathway as a possible future target for developing novel drugs toward this still unmet clinical need. However, evidence is still limited and future studies are needed to further clarify the relationship between kynurenine pathway and cognition in schizophrenia.Keywords
Funding Information
- Ministero della Salute (GR-2019-12369523, GR-2019-12369523)
- Macquarie University
This publication has 81 references indexed in Scilit:
- Meta-Analysis of Oxidative Stress in SchizophreniaBiological Psychiatry, 2013
- COMT Val158Met polymorphism interacts with stressful life events and parental warmth to influence decision makingScientific Reports, 2012
- Effects of Kynurenine Pathway Inhibition on NAD+ Metabolism and Cell Viability in Human Primary Astrocytes and NeuronsInternational Journal of Tryptophan Research, 2011
- Cortical Kynurenine Pathway Metabolism: A Novel Target for Cognitive Enhancement in SchizophreniaSchizophrenia Bulletin, 2010
- Schizophrenia, “just the facts” 4. Clinical features and conceptualizationSchizophrenia Research, 2009
- The Dopamine Hypothesis of Schizophrenia: Version III--The Final Common PathwaySchizophrenia Bulletin, 2009
- Menopause alters the metabolism of serum serotonin precursors and their correlation with gonadotropins and estradiolClimacteric, 2007
- The effect of age on the enzyme activities of tryptophan metabolism along the kynurenine pathway in ratsClinica Chimica Acta, 2005
- Sex differences in schizophrenia, a review of the literatureActa Psychiatrica Scandinavica, 2000
- Blood–Brain Barrier Transport of Kynurenines: Implications for Brain Synthesis and MetabolismJournal of Neurochemistry, 1991